FOXM1 is a promising molecular target in newly diagnosed high-risk myeloma (HRMM) [1] and relapsed/refractory myeloma (RRMM) [2, 3], but the mechanism with which FOXM1 promotes plasma cell neoplasia is poorly understood. The gene discussed is FOXM1; the disease is plasma cell myeloma.